281 related articles for article (PubMed ID: 19370737)
1. Randomized controlled trial of memantine in dementia associated with Parkinson's disease.
Leroi I; Overshott R; Byrne EJ; Daniel E; Burns A
Mov Disord; 2009 Jun; 24(8):1217-21. PubMed ID: 19370737
[TBL] [Abstract][Full Text] [Related]
2. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.
Aarsland D; Ballard C; Walker Z; Bostrom F; Alves G; Kossakowski K; Leroi I; Pozo-Rodriguez F; Minthon L; Londos E
Lancet Neurol; 2009 Jul; 8(7):613-8. PubMed ID: 19520613
[TBL] [Abstract][Full Text] [Related]
3. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease.
Reisberg B; Doody R; Stöffler A; Schmitt F; Ferris S; Möbius HJ
Arch Neurol; 2006 Jan; 63(1):49-54. PubMed ID: 16401736
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial of memantine as treatment for spasticity in multiple sclerosis.
Mehta LR; McDermott MP; Goodman AD; Schwid SR
Mult Scler; 2010 Feb; 16(2):248-51. PubMed ID: 20028712
[TBL] [Abstract][Full Text] [Related]
5. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study.
Merello M; Nouzeilles MI; Cammarota A; Leiguarda R
Clin Neuropharmacol; 1999; 22(5):273-6. PubMed ID: 10516877
[TBL] [Abstract][Full Text] [Related]
6. Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study.
Görtelmeyer R; Erbler H
Arzneimittelforschung; 1992 Jul; 42(7):904-13. PubMed ID: 1418054
[TBL] [Abstract][Full Text] [Related]
7. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.
Poewe W; Wolters E; Emre M; Onofrj M; Hsu C; Tekin S; Lane R;
Mov Disord; 2006 Apr; 21(4):456-61. PubMed ID: 16229010
[TBL] [Abstract][Full Text] [Related]
8. Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients.
Barone P; Burn DJ; van Laar T; Hsu C; Poewe W; Lane RM
Mov Disord; 2008 Aug; 23(11):1532-40. PubMed ID: 18581467
[TBL] [Abstract][Full Text] [Related]
9. A pilot double-blind treatment trial of memantine for alcohol dependence.
Evans SM; Levin FR; Brooks DJ; Garawi F
Alcohol Clin Exp Res; 2007 May; 31(5):775-82. PubMed ID: 17378918
[TBL] [Abstract][Full Text] [Related]
10. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
Pomara N; Ott BR; Peskind E; Resnick EM
Alzheimer Dis Assoc Disord; 2007; 21(1):60-4. PubMed ID: 17334274
[TBL] [Abstract][Full Text] [Related]
11. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial.
Emre M; Tsolaki M; Bonuccelli U; Destée A; Tolosa E; Kutzelnigg A; Ceballos-Baumann A; Zdravkovic S; Bladström A; Jones R;
Lancet Neurol; 2010 Oct; 9(10):969-77. PubMed ID: 20729148
[TBL] [Abstract][Full Text] [Related]
12. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study.
Schifitto G; Navia BA; Yiannoutsos CT; Marra CM; Chang L; Ernst T; Jarvik JG; Miller EN; Singer EJ; Ellis RJ; Kolson DL; Simpson D; Nath A; Berger J; Shriver SL; Millar LL; Colquhoun D; Lenkinski R; Gonzalez RG; Lipton SA; ; ;
AIDS; 2007 Sep; 21(14):1877-86. PubMed ID: 17721095
[TBL] [Abstract][Full Text] [Related]
13. A double-blind, placebo-controlled trial of memantine in age-associated memory impairment (memantine in AAMI).
Ferris S; Schneider L; Farmer M; Kay G; Crook T
Int J Geriatr Psychiatry; 2007 May; 22(5):448-55. PubMed ID: 17117395
[TBL] [Abstract][Full Text] [Related]
14. Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial.
Ondo WG; Shinawi L; Davidson A; Lai D
Parkinsonism Relat Disord; 2011 Mar; 17(3):156-9. PubMed ID: 21193343
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis.
Maidment ID; Fox CG; Boustani M; Rodriguez J; Brown RC; Katona CL
Ann Pharmacother; 2008 Jan; 42(1):32-8. PubMed ID: 18056833
[TBL] [Abstract][Full Text] [Related]
16. Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy.
Hartmann S; Möbius HJ
Int Clin Psychopharmacol; 2003 Mar; 18(2):81-5. PubMed ID: 12598818
[TBL] [Abstract][Full Text] [Related]
17. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease.
Hauser RA; Lyons KE; McClain T; Carter S; Perlmutter D
Mov Disord; 2009 May; 24(7):979-83. PubMed ID: 19230029
[TBL] [Abstract][Full Text] [Related]
18. Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies.
Wesnes KA; Aarsland D; Ballard C; Londos E
Int J Geriatr Psychiatry; 2015 Jan; 30(1):46-54. PubMed ID: 24737460
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
Wilkinson D; Andersen HF
Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
[TBL] [Abstract][Full Text] [Related]
20. A 6-month, open-label study of memantine in patients with frontotemporal dementia.
Diehl-Schmid J; Förstl H; Perneczky R; Pohl C; Kurz A
Int J Geriatr Psychiatry; 2008 Jul; 23(7):754-9. PubMed ID: 18213609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
